Product Datasheet

TDO2 Antibody (OTI2A4)
NBP2-45995

Unit Size: 0.1 ml

Store at -20C. Avoid freeze-thaw cycles.

www.novusbio.com technical@novusbio.com

Publications: 3

Protocols, Publications, Related Products, Reviews, Research Tools and Images at:
www.novusbio.com/NBP2-45995

Updated 9/9/2025 v.20.1



NBP2-45995

TDO2 Antibody (OTI2A4)

Product Information	
Unit Size	0.1 ml
Concentration	1 mg/ml
Storage	Store at -20C. Avoid freeze-thaw cycles.
Clonality	Monoclonal
Clone	OTI2A4
Preservative	0.02% Sodium Azide
Isotype	IgG1
Purity	Immunogen affinity purified
Buffer	PBS (pH 7.3), 1.0% BSA and 50% Glycerol
Target Molecular Weight	47.7 kDa

Product Description	
Description	Novus Biologicals Mouse TDO2 Antibody (OTI2A4) (NBP2-45995) is a monoclonal antibody validated for use in WB. Anti-TDO2 Antibody: Cited in 3 publications. All Novus Biologicals antibodies are covered by our 100% guarantee.
Host	Mouse
Gene ID	6999
Gene Symbol	TDO2
Species	Human
Immunogen	Full length human recombinant protein of human TDO2(NP_005642) produced in HEK293T cell.

Product Application Details	
Applications	Western Blot
Recommended Dilutions	Western Blot 1:2000

Images

Western Blot: TDO2 Antibody (OTI2A4) [NBP2-45995] -Analysis of overexpressed lysates(15ug per lane) from HEK293T cells transfected with empty plasmid , lane 1) , human TDO2 plasmid , lane 2), mouse TDO2 plasmid, lane 3) using anti-TDO2 antibody (1:500). Figure B, Western blot analysis of the same samples as figure A with anti-DDK antibody, 1:1000)



IDO1-mediated KYN production from CR cells suppressed immunomodulatory profile. A Immunoblot of IDO1, IDO2, and TDO2. Resistant cells were treated with either IDO1 inhibitor or shRNA targeting IDO1 (shCTRL represents scramble sequence, shIDO A, B, and C represent 3 unique shRNA sequences). B Detection of amino acid KYN and TRP concentrations in culture supernatants using Amino Acid Analyzer Biochrome30 + . C Immune profile of CS vs. CR co-cultured with hPBMC. Using the same experimental condition as Fig. 1E above, IDO1 inhibitions significantly enhanced the percent of NKG2D on NK cells (CD3-CD56 + NKG2D +) and the percent of NKG2D on CD8 + (CD3 + CD8 + NKG2D +) cells, but significantly suppressed Treg (CD4 + CD25 + FoxP3 +) and MDSC (HLA-DR.loCD14-CD11b + CD33 +) populations (see the gating strategy in Supplemental Figure S1). D The indicated cytokines are quantified in culture supernatants by LEGENDplex™ bead-based immunoassay. The panel below indicated that anti-NKG2D blocking antibodies blunt the effect of IDO1 inhibition. Note: To detect the MDSC population, cells were activated by PHA + IL2 instead of antiCD2/28 + IL2. Cell lines A and FA are cisplatin-sensitive, and ALC and FC are cisplatin-resistant counterparts. In all experiments, data presented as mean +/- SEM of 3 independent experiments and were analyzed using one-way ANOVA followed by Tukey's multiple comparison analysis with *P < 0.05, **P < 0.005, ***P < 0.0005, ****P < 0.0001 Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/37226257), licensed under a CC-BY license. Not internally tested by Novus Biologicals.



Publications

Arnaud Jacquerie, Ann Hoeben, Daniëlle B. P. Eekers, Alida A. Postma, Maxime Vanmechelen, Frederik de Smet, Linda Ackermans, Monique Anten, Kim Severens, Axel zur Hausen, Martinus P. G. Broen, Jan Beckervordersandforth Prognostic relevance of high expression of kynurenine pathway markers in glioblastoma Scientific Reports 2024-06-28 [PMID: 38951170]

Wu C, Spector S, Theodoropoulos G et al. Dual inhibition of IDO1/TDO2 enhances anti-tumor immunity in platinum-resistant non-small cell lung cancer Research Square 2022-10-27 [PMID: 37226257] (WB)

Hao S, Huang G, Feng J et al. Non-NF2 mutations have a key effect on inhibitory immune checkpoints and tumor pathogenesis in skull base meningiomas J. Neurooncol. 2019-06-08 [PMID: 31177425]

Novus Biologicals USA
10730 E. Briarwood Avenue
Centennial, CO 80112
USA
Phone: 303.730.1950
Toll Free: 1.888.506.6887
Fax: 303.730.1966
nb-customerservice@bio-techne.com

Bio-Techne Canada
21 Canmotor Ave
Toronto, ON M8Z 4E6
Canada
Phone: 905.827.6400
Toll Free: 855.668.8722
Fax: 905.827.6402
canada.inquires@bio-techne.com

Bio-Techne Ltd
19 Barton Lane
Abingdon Science Park
Abingdon, OX14 3NB, United Kingdom
Phone: (44) (0) 1235 529449
Free Phone: 0800 37 34 15
Fax: (44) (0) 1235 533420
info.EMEA@bio-techne.com

General Contact Information
www.novusbio.com
Technical Support: nb-technical@bio-techne.com
Orders: nb-customerservice@bio-techne.com
General: novus@novusbio.com

Products Related to NBP2-45995

NBP2-33376H	Blue Marker Antibody (6F4-F6) [HRP]
HAF007	Goat anti-Mouse IgG Secondary Antibody [HRP]
NB7539	Goat anti-Mouse IgG (H+L) Secondary Antibody [HRP]
NBP1-97005-0.5mg	Mouse IgG1 Isotype Control (MG1)

Limitations
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

For more information on our 100% guarantee, please visit www.novusbio.com/guarantee

Earn gift cards/discounts by submitting a review: www.novusbio.com/reviews/submit/NBP2-45995

Earn gift cards/discounts by submitting a publication using this product: www.novusbio.com/publications